Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a plasma treatment beat serum for aniridia eye damage?

NCT ID NCT05400590

Knowledge-focused Sponsor: Fondation Ophtalmologique Adolphe de Rothschild Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at two treatments made from patients' own blood—autologous serum and growth factor-rich plasma—to see which helps heal the cornea better in people with aniridia, a rare eye condition. Researchers will test these treatments on corneal cells in the lab, using blood and cell samples from 24 participants (12 with aniridia and 12 healthy controls). The goal is to find a way to reduce scarring and improve healing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
growth factor-rich plasma and autologous serum
What this could lead to
If successful, this could point toward a better treatment for corneal clouding in aniridia patients, potentially reducing scarring.
What could go wrong
This is a small, early-stage lab study with only 24 participants, so results may not translate to real-world healing or benefit all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2023

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Aniridia patients and controls without aniridia

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For patients with aniridia: * With aniridia * Patient weighing more than 43 kg * If the patient is being treated with autologous serum, a delay of 8 weeks after the last blood collection * If a blood donation has been made, a delay of 8 weeks must be respected after the last donation For controls: * Non-aniridia (no clinical signs) * Weighing more than 43 kg * Matched to a case for sex and age +/-10 years * No known diabetes * If a blood donation has been made, a delay of 8 weeks must be respected after the latter Exclusion Criteria: * Insufficient sample volume * No conjunctival print * HBV, HCV, HIV serology positive * Aniridia not genetically confirmed for cases For each patient excluded, a new patient will be included in order to maintain the number of patients required for data analysis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aniridia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aniridia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aniridia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpital Fondation A. de Rothschild

    RECRUITING

    Paris, 75019, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.